Authors
Latest:
Dr Christensen on the Influence of Patient Selection for BCL-2 Inhibitor Treatment in AMLBradley W. Christensen, MD, discusses the process of patient selection for BCL-2 induction therapy in patients with acute myeloid leukemia in accordance with their individual disease characteristics.
Latest:
Comprehensive Treatment Advances Care for Patients With Early-Stage Breast CancerAdvances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.
Latest:
Ruxolitinib in the Treatment of PVKey opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.
Latest:
Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple MyelomaDickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.
Latest:
Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in LymphomaIra Braunschweig, MD, discusses mitigating the toxicities that are associated with CAR T-cell therapy in lymphoma.
Latest:
Dr. Blackwood on the Implementation of the I SPY2 Trial in Breast CancerM. Michele Blackwood, MD, FACS, discusses the implementation of the phase 2 I-SPY 2 trial in breast cancer at Robert Wood Johnson Medical Center.
Latest:
Dr King on Teratoma in Residual Nonretroperitoneal Disease After Chemotherapy for Testicular CancerJennifer M. King, MD, discusses results from a retrospective study on the prevalence of teratoma and active germ cell tumors in patients who have residual nonretroperitoneal disease following chemotherapy for nonseminomatous germ cell tumors, and what these findings indicate about the need for surgical resection in this patient population.
Latest:
University of Chicago Medical Center Ranks Among Nation’s Best in 10 Specialties, According to U.S. News SurveyThe University of Chicago Medical Center ranks among the nation’s best hospitals in 10 specialties, according to results of the U.S. News & World Report’s annual survey.
Latest:
Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIsAmanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.
Latest:
NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion MutationsBefore closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.
Latest:
Dr Kesireddy on the Future Use of Capivasertib Plus Fulvestrant in HR+/HER2– Breast CancerMeghana Kesireddy, MBBS, discusses the pending FDA approval of the AKT inhibitor capivasertib plus the selective estrogen receptor degrader fulvestrant in patients with hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract CancerMojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.
Latest:
Dr Massarelli on Addressing Unmet Needs in SCLCErminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.
Latest:
Beyond the Clinic: Leveraging Research to Tackle Lung Cancer DisparitiesLung cancer remains the most common cause of cancer death in the United States.
Latest:
Dr. Mark on Questions Regarding Sequencing in Multiple MyelomaTomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.
Latest:
Drs Gerber and Nwachukwu on the Importance of Streamlining Clinical Research in Cancer CareDavid Gerber, MD, and Chika Nwachukwu, MD, PhD, discuss their role within the Stand Up To Cancer® 4-team initiative, focusing on diversity in early-phase clinical trials.
Latest:
Dr. Venkat on Unmet Needs in Ovarian CancerPuja S. Venkat, MD, discusses unmet needs in ovarian cancer.
Latest:
Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLCYasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.
Latest:
Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPCBilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.
Latest:
Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETsNitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial CancerDario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.
Latest:
Dr. Weiss on Selecting Optimal Radiation Therapy for Brain MetastasesStephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.
Latest:
Dr Huang on the Use of Neoadjuvant PARP Inhibitors in Advanced Ovarian CancerMarilyn Huang, MD, discusses the need for non-chemotherapy options in advanced ovarian cancer, as well as data on the use of neoadjuvant PARP inhibitors for this population in the phase 1 NOW study.
Latest:
Dr. Mahal on the Emerging Role of Epigenomics in Prostate CancerBrandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.
Latest:
The COVID-19 Pandemic Will Have Long-Term Impact on Oncology PracticesThe COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.
Latest:
Cleveland Clinic Opens New Cancer Center in Abu DhabiCleveland Clinic has opened a new state-of-the-art cancer facility, named the Fatima bint Mubarak Center, at Cleveland Clinic Abu Dhabi.
Latest:
Dr Girda on the Use of Pembrolizumab Plus Chemotherapy in Endometrial CancerEugenia Girda, MD, FACOG, discusses the use of pembrolizumab plus chemotherapy for patients with endometrial cancer as seen in the phase 3 NRG-GY018 trial.
Latest:
HCC International Clinical TrialsClosing the discussion on HCC systemic therapies, Drs Abou-Alfa, Lewandowski and Singal review international clinical trials and access to treatments.
